Association of F2-isoprostane levels with Alzheimer’s disease in observational studies: A systematic review and meta-analysis

The association between F2-isoprostanes and Alzheimer’s disease (AD) has been controversially discussed in the literature since the 1990s. However, no systematic review has been performed so far. A systematic review of observational studies on the associations of F2-isoprostanes and the specific bio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ageing research reviews 2022-02, Vol.74, p.101552-101552, Article 101552
Hauptverfasser: Trares, Kira, Chen, Li-Ju, Schöttker, Ben
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The association between F2-isoprostanes and Alzheimer’s disease (AD) has been controversially discussed in the literature since the 1990s. However, no systematic review has been performed so far. A systematic review of observational studies on the associations of F2-isoprostanes and the specific biomarker 8-iso-prostaglandin F2α with AD were conducted. Random-effects model meta-analyses were performed. 29 studies were included in the systematic review, including four longitudinal studies. In an overall meta-analysis of the 25 cross-sectional studies, F2-isoprostane levels were statistically significantly associated with AD (Hedge’s g [95% confidence interval]: 1.00 [0.69–1.32]). When studies were grouped by biomarker and sample specimen, F2-isoprostane and 8-iso-prostaglandin F2α levels were statistically significantly elevated in tissue samples of the frontal lobe of AD patients. Moreover, F2-isoprostane levels in cerebrospinal fluid and 8-iso-prostaglandin F2α levels in blood samples of AD patients were significantly increased. Meta-analyses of the few longitudinal studies did not reach statistical significance. Increased concentrations of F2-isoprostanes were found in AD patients. However, due to the lack of adjustment in most cross-sectional case-control studies, results must be interpreted carefully. In addition, the causality of the association is uncertain because evidence from well-conducted longitudinal studies was conflicting, and further longitudinal studies are required to reinforce the results. •F2-isoprostanes are statistically significantly elevated in Alzheimer’s disease patients.•This increase was especially present in F2-isoprostanes analysed in in cerebrospinal fluid and frontal lobe tissue samples.•An association between F2-isoprostanes and Alzheimer’s disease in studies with blood samples was also found.•More longitudinal studies are needed because current evidence is mainly from cross-sectional studies.
ISSN:1568-1637
1872-9649
DOI:10.1016/j.arr.2021.101552